PMOS Recognizes Insulin Resistance and Weight as Metabolic Features of PCOS
The hormonal condition known as polycystic ovary syndrome (PCOS) is being renamed polyendocrine metabolic ovarian syndrome (PMOS). The new terminology, endorsed by a 14‑year global consensus and published in The Lancet, removes the reference to ovarian cysts and incorporates “metabolic” to reflect the disorder’s insulin‑resistance and weight‑related aspects. The revision was led by Professor Helena Teede of Monash University and involved more than 22,000 survey responses and international workshops with patients and clinicians.
PMOS Recognizes Insulin Resistance and Weight as Metabolic Features of PCOS
The acronym PMOS highlights the syndrome’s endocrine (polyendocrine) and metabolic components, with “metabolic” directly referencing insulin resistance and obesity. This framing more accurately describes the physiological profile of the condition, as noted in a summary published by Contemporary OB/GYN.
PMOS Will Fully Replace the PCOS Name by 2028
According to the Monash University announcement and the Lancet authors, the former name suggested pathologically enlarged ovarian cysts while obscuring the condition’s endocrine and metabolic dimensions. This mischaracterisation has contributed to delayed diagnoses and stigma for affected individuals.
PMOS Will Fully Replace the PCOS Name by 2028
A three‑year transition plan, supported by an international education campaign, will phase in PMOS as the standard terminology. Full adoption is slated for the 2028 update of the international clinical guidelines for the syndrome.
Weight as Part of a Metabolic Picture
Under the PMOS model, body weight is considered within a broader metabolic context that includes insulin resistance. This perspective aligns with emerging understandings of metabolic health, which examine visceral fat and lean mass in addition to overall weight, as emphasized by experts in the field.
Also Read
- Medicaid Work Rules: Hardship Exemption Could Cover 95 Counties, but States Must Act
- Pediatrician, Pastor, and Paralympian Join Forces to Advance Children’s Mental Health
- Democratic Congressional Sweep Sets Stage for Sweeping Federal Health Policy Overhaul
- Servier’s $1.5 Billion Muscle Drug Fails Late-Stage Becker Muscular Dystrophy Trial
